Certain conditions exist which may allow the distribution of information con cerning off-label uses of drugs. For drug approval; the Food and Drug Administration Modernization Act (F DAMA section 401) has to have information for a drug or device that has been approved by the FDA. However according the new 2009 Guidance, the s tatus of the drug-approval is not mentioned. For the filing of a supplemental New Drug Application, the FDAMA requires that the manufacturer submit a supplemental New Drug Application for a n ew use or studies. In the new guidance, nothing is mentioned, but compani es are encouraged to seek approval for new uses or indications. In the advance provision to the FDA, the company must submit all informati on concerning efficacy and safety of the drug 60 days before dissemination . In the new guidance, it is not mentioned. For the source of underlying clinical data, it has to be accurate resulting from serious well controlled clinical studies and trials according to the FD AMA and the new guidance of 2009. Concerning the subject of accuracy, the FDAMA requires that the informatio n must be accurate, true, and not misleading, conclusions must be appropri ate and the information must not pose a threat to public safety. Other saf ety and efficacy information can be required from the manufacturer. The sa me applies to the new guidance of 2009. For the provision of countervailing scientific findings, the information mus t be provided with approved labeling and a complete bibliography of publicat ions concerning the off-label uses (including unfavorable studies) and other information concerning risks of this new use. The new guidance requires the same comprehensive bibliography of publications related to the off-label us e, and also other publications concerning this use that are opposite or diff erent. The required disclosures must state that the off-label use is not FDA -appr oved and must identify other products that are FDA-approved for that same u se. The new guidance disclosure's statement identifies study sponsors, fina ncial interests, and should mention any known risks not discussed in the pu blication. The presentation of journal article includes the unabridged article or sect ion of reference publication. Company representatives may not verbally prom ote the new use, and no promotional materials should be included in the pub lication. The new guidance adds that the publication unabridged should not be highlighted, summarized or differentiate in any way. The journal requirements, the information should be published in peer-revi ewed scientific or medical journals (listed in Index Medicus). Also unabri dged reference texts can be distributed without highlighting the off-label unapproved use. No company supplement should be used. According to the ne w guidance, the information should be published by organizations with peer -review procedures and a panel of experts. And the new information cannot appear in company funded supplement or publication. The distribution must be restricted to health care practitioners, pharmacy managers, health insurers, group health plans and federal and state agencie s. The distribution to consumers is not allowed. The new guidance adds that information should be provided separately from promotional information and the distribution should be restricted to the same as above mentioned. For the other avenues of dissemination, the company can give information a bout off-label uses in response to special requests from healthcare practi tioners. The new guidance agrees with the FDAMA.
Pages to are hidden for
"Information Abou"Please download to view full document